POSITION PAPER. National Psoriasis Foundation. ** Present or past member of the Board of the National Psoriasis
|
|
- Bertha Day
- 8 years ago
- Views:
Transcription
1 POSITION PAPER Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? Gerald G. Krueger, MD, a,* Steven R. Feldman, MD, PhD, b,* Charles Camisa, MD, c, Madeleine Duvic, MD, d,* James T. Elder, MD, PhD, e,* Alice B. Gottlieb, MD, PhD, f John Koo, MD, g James G. Krueger, MD, h, Mark Lebwohl, MD, i,* Nicholas Lowe, MD, j Alan Menter, MD, k Warwick L. Morison, MD, l,* Janet H. Prystowsky, MD, PhD, m,* Jerome L. Shupack, MD, n,* J. Richard Taylor, MD, o,* Gerald D. Weinstein, MD, p,* Thomas L. Barton, q,** Tara Rolstad, r and Robert M. Day, PhD s,** Salt Lake City, Utah; Cleveland, Ohio; Houston and Dallas, Texas; Ann Arbor, Michigan; Winston-Salem, North Carolina; New Brunswick, New Jersey; San Francisco, Santa Monica, Irvine, and Palo Alto, California; New York, New York; Lutherville, Maryland; Miami, Florida; Portland, Oregon; and Charlottesville, Virginia The definitions of psoriasis severity and clinically significant improvement in psoriasis are used to classify treatments, obtain Food and Drug Administration approval, and determine product labeling and reimbursement. The Medical Advisory Board of the National Psoriasis Foundation has addressed these issues because of their importance in the clinical trials that are conducted to gain FDA approval of indications. Narrow indications, which are without a sound rational basis, will in this era of constant oversight by third party payers affect physicians ability to manage patients with psoriasis. Body surface area (BSA) is usually used to define severity for clinical trials. It is not optimal for defining psoriasis severity because there are some patients with low BSA involvement who have very severe psoriasis and some patients with high BSA involvement who have mild psoriasis. We conclude that a quality of life (QOL) standard is better than BSA measurement for identifying patients with severe psoriasis. The second issue is what defines clinically significant improvement for patients with psoriasis. Setting an arbitrarily high criterion of clinical efficacy for new psoriasis treatments will likely limit the development and approval of useful treatments. To maximize the availability of useful psoriasis treatments, it is our thesis that psoriasis treatments should be approved when they have been shown to produce a statistically significant level of improvement in well-designed clinical trials. (J Am Acad Dermatol 2000;43:281-5.) From the Department of Dermatology, University of Utah, Salt Lake City a ; the Department of Dermatology, Cleveland Clinic Foundation b ; Section of Dermatology, M. D. Anderson Cancer Center, Houston c ; Department of Dermatology and Radiation Oncology, University of Michigan d ; Department of Dermatology, Bowman Gray School of Medicine, Winston-Salem e ; Clinical Research Center, UMDNJ-Robert Wood Johnson Medical School, New Brunswick f ; Psoriasis Treatment Center, University of California San Francisco g ; Investigative Dermatology, The Rockefeller University, New York h ; Department of Dermatology, Mount Sinai Medical Center, New York i ; Santa Monica j ; Division of Dermatology, Baylor University, Dallas k ; Department of Dermatology, Johns Hopkins Medical Institutions, Lutherville l ; Department of Surgery, Columbia-Presbyterian Medical Center, New York m ; New York University School of Medicine n ; University of Miami/Veterans Affairs Medical Center o ; Department of Dermatology, University of California, Irvine p ; Manatt, Phelps and Phillips, Palo Alto q ; National Psoriasis Foundation, Portland r ; and Pharmaceutical Research Associates, Inc, Charlottesville. s Reprints not available from authors. * Present or past member of the Medical Advisory Board of the National Psoriasis Foundation. ** Present or past member of the Board of the National Psoriasis Foundation. Clinicians actively participating in clinical research trials on psoriasis and concerning the issues represented in this article. Copyright 2000 by the American Academy of Dermatology, Inc /2000/$ /1/ doi: /mjd
2 282 Krueger et al J AM ACAD DERMATOL AUGUST 2000 BACKGROUND TO A DEFINITION OF MILD, MODERATE, AND SEVERE PSORIASIS Severity of psoriasis: A view from the clinic Psoriasis vulgaris is a complex, multifaceted skin condition, the pathogenesis of which is still poorly understood. 1-3 The characteristic scaly, red, indurated lesion of psoriasis typically varies as a function of time relative to the size of the lesion, the areas of involvement, the percentage of the body surface covered with disease, the complaint of pruritus, burning and/or pain in the lesions, and the associated arthropathy. 4,5 Thus in any given patient severity will fluctuate and with it the impact of psoriasis on patients. These features make quantification of the severity of the disease difficult 6,7 and raise the question: What are the key features that define the severity of psoriasis? Is it the redness, scale, or induration? Is it the extent of the disease, the percentage of body surface area affected? Is it the degree of itching? Is it the impact that it has on patients lives? Is it all of these? The terms mild, moderate, and severe psoriasis are commonly used, but there are no standard criteria for them. How should they be defined? Can a specific definition be developed that is applicable in all settings? Definition of these terms is important in clinical care and in clinical research studies to identify and characterize new safe and efficacious treatments. Despite the lack of a uniformly accepted definition, these terms are used to classify treatments and to obtain FDA approval, product labeling, and, potentially, reimbursement. While regulatory agencies are considering this issue, one purpose of this position paper is to bring the issue to the attention of dermatologists and their patients. The Medical Advisory Board of the National Psoriasis Foundation does so with the goal of generating a definition of severity that is clinically relevant. Doing this makes outcomes of clinical trials transferable to clinical practice and brings consistency to the inclusion and exclusion criteria of patients in clinical trials. For patients and their physicians, severity is inexorably linked to the impact psoriasis has on QOL Treatment decisions need to focus on the complex interplay between the severity of skin lesions and their impact on the patient and on the costs and risks to the patient relative to the expected benefits. 13 Severity of psoriasis: A view from the new drug approval process To further appreciate the significance of this position paper, it is necessary to understand the current drug approval process for the treatment of psoriasis. First, there are preclinical studies that demonstrate a profile of activity (eg, anti-inflammatory properties, antiproliferative properties, antiangiogenesis properties) which suggests the drug may have an effect on any or all aspects of the clinical manifestations of psoriasis. Phase II safety and dose-ranging trials in normal people or patients with psoriasis ensue; a lack of significant toxicity and a potential for efficacy lead to dose-to-efficacy studies. If data from these trials indicate efficacy and acceptable toxicity, pivotal phase III studies are implemented. These compare a set dose(s) and duration of therapy with placebo in achieving predetermined end points. The severity of psoriasis required for patients entering these trials is determined in meetings with the FDA. Typically the pivotal study is conducted in patients with the same severity of disease as the phase II trials. If the new drug is to be administered systemically, the current FDA policy dictates that only patients with severe psoriasis be enrolled. For unknown reasons regulatory agencies and pharmaceutical companies have chosen to define psoriasis on the basis of percentage of body surface area (BSA) affected with psoriasis. Severe disease has frequently been defined as more than 20% BSA affected with psoriasis; more recently the Medical Advisory Board notes that occasionally the FDA has accepted 10% BSA as an indication of severe disease. At the end of the pivotal trial the data are analyzed. If the new drug is significantly better than the placebo relative to the predetermined end points and has an acceptable safety profile and potential in the marketplace, a New Drug Application (NDA) is filed with the FDA. An in-depth review process follows. Barring unexpected findings, the new drug is approved for the indication studied in the phase III trial. Because denial of reimbursement for new drugs for indications outside the approved indication (eg, severe psoriasis) is now commonplace, the definition of severity becomes critically important. Strict BSA definitions are currently being recommended for studies of new biotechnology therapies for psoriasis. Envision that a new drug XYZ has been tested and approved using such a BSA criterion for severe psoriasis. The clinical trials have shown that it is very effective (ie, will produce 90% or more improvement in 50% of subjects who take it for the prescribed course) and that it has essentially no side effects. It is probable that XYZ is very expensive. A patient with 5% BSA learns about XYZ and its favorable therapeutic index and wants to try it. The consulting dermatologist believes XYZ is appropriate because the patient s disease is disfiguring, painful, is having a negative impact on QOL, and has proven to be resistant to topical treatments. A prescription is written for XYZ ; the patient takes it to the pharma-
3 J AM ACAD DERMATOL VOLUME 43, NUMBER 2, PART 1 Krueger et al 283 Table I. A quality of life based definition of mild psoriasis Disease does not alter the patient s quality of life. Patients can minimize the impact of disease and may not require treatment. Treatments have no known serious risks (eg, class 5 topical steroids). Generally less than 5% of body surface area is involved with disease. cy and is told that the prescription cannot be filled without documentation of severity of disease. The records note that the patient has 5% BSA. This does not coincide with the definition of severe in the package insert (already BSA is listed as a criterion in the package insert information for use of topical tazarotene), and reimbursement is denied. In this scenario the patient and then the doctor may become frustrated, disappointed, and angry, largely as a result of an inappropriate definition of severity. It is our position that BSA is not a rational definition of severity because there are some patients with low BSA involvement who have very severe psoriasis and some patients with high BSA involvement who have mild psoriasis. We conclude that a more rational definition of severity needs to be generated to facilitate the development and accessibility of treatments for patients with psoriasis. After considerable and prolonged consideration, we conclude that the severity of psoriasis is, first and foremost, a QOL issue. The complexity of determining what constitutes severe psoriasis: An illustration This issue can be appreciated by considering which of the following 4 patients has severe psoriasis: Patient A: 20% BSA involved with psoriasis Patient B: 10% BSA involved with psoriasis Patient C: 5% BSA involved with psoriasis Patient D: 1% BSA involved with psoriasis Consider each of these patients with the following caveats: Patient A has obvious widespread disease. This person s disease is recognized by all as severe and therefore must alter the QOL. However, would it still be severe if it was not in the scalp, it was only on covered parts of the body, and the lesions were thin and did not itch? Patient B also has obvious disease, and most would consider it severe, especially if it is painful, bleeds frequently, and provokes constant itching. Patient C has less obvious disease; however, if the face and scalp have thick indurated plaques, most would consider this patient as having severe disease. Table II. A quality of life based definition of moderate psoriasis Disease does alter the patient s quality of life. The patient expects therapy will improve quality of life. Therapies used for moderate disease have minimal risks (ie, although these therapies may be inconvenient, expensive, time-consuming, and less than totally effective, they are not recognized as having the potential for altering short- or long-term health). Generally between 2% and 20% of body surface area is involved with disease. Patient D has even less obvious disease; however, if it were all on the dominant hand, affecting daily activities, most would consider this patient as having severe disease. Consider also the patient with essentially no skin lesions but who has arthritis that interferes with his or her performance in the workplace. Conversely, consider patients who, on the basis of BSA, have severe disease but have modifying aspects that make it more appropriate to classify them as having moderate or perhaps even mild disease. The first example could be the unusual patient with 20% or more BSA affected with psoriasis who elects not to be treated; does this patient truly have severe disease? A second example could be a patient with 10% BSA affected who only wants treatments that have minimal to no side effects and is able to cope with significant residual disease after a course of such a treatment; does this patient truly have severe disease? These iterations, which are not uncommon, strengthen our thesis; the severity of psoriasis is, and actually always has been, a QOL issue. A QOL-based definition of the severity of psoriasis Tables I to IV define psoriasis in a fashion that encompasses the patients perceptions (the varying ability of patients to accept side effects, the hassle of topical and ultraviolet light (UVL) based treatments, the costs, and the lack of complete efficacy and toxicity of current treatments 14,15 ) and the prescribing habits of physicians. It is important to note that if there were an oral medication that worked every time, did not have associated side effects, and did not have contraindications, we would have a much different attitude about what defines severity. Although such a treatment is not currently available, this concept does make it necessary to realize that any definition of severity could change. It is also very important to appreciate, as Tables I, II, and III demonstrate, that moderate for one patient may be mild or severe for another.
4 284 Krueger et al J AM ACAD DERMATOL AUGUST 2000 Table III. A quality of life based definition of severe psoriasis Disease alters the patient s quality of life. Disease does not have a satisfactory response to treatments that have minimal risks. Patients are willing to accept life-altering side effects to achieve less disease or no disease. Generally more than 10% of body surface area is involved with disease. Other factors Patient s attitude about disease Location of disease (eg, face, hands, fingernails, feet, genitals) Symptoms (eg, pain, tightness, bleeding, or severe itching) Arthralgias/arthritis Dermatologists who offer a complete array of treatments for psoriasis (topical, UVL-based, and oral therapies) have learned how to assess the severity of disease; this assessment includes the needs of the patient, the time needed for treatment, the cost of treatment, the benefit of the treatment and the willingness of the patient to accept potential life-altering side effects to achieve a better QOL. We argue that it is unreasonable to base the severity issue solely on BSA, not only for clinical trials but in everyday clinical assessments. As Table IV illustrates, there are multiple factors that encompass a clinical definition of severity issue. Because of the nature of a disease that has physical, social, and psychologic components, elements in Table IV overlap. Specific aspects of psoriasis whose impact on QOL have been quantitated include appearance of the skin, scales falling off, itching, burning sensations, joint pain, skin soreness, appearance of joints or bones, time it takes to care for psoriasis, monetary cost of treatment, stains on clothing or furniture, time lost from work, hair loss, medication side effects, unpleasant odors, doctors attitude toward psoriasis, people staring or reacting negatively, avoidance by people, self-consciousness about the skin, and inability to control the psoriasis. 11,12,14 It would be useful to bring a quantitative scale to each of these; however, because each patient has different limits of tolerance, that would be difficult and perhaps impossible. Our objective is not to generate a new quantitative assessment of psoriasis. Rather, it is to cause practitioners, pharmacy-benefit managers, insurers, and regulatory agencies such as the FDA to realize that BSA is not an accurate reflection of severity but instead to use and approve agents on a QOL basis. Table IV. Considerations in a clinically based definition of severe psoriasis Psoriasis has a broad impact on health-related quality of life. 11,12 Severity of psoriasis is linked to the ways in which the disease alters the many dimensions of quality of life in the following 3 broad categories. Note: These categories can and do overlap. Impact on daily physical activities; the role of psoriasis on routine activities at work, school and home. Included in this are performance on the job, school, or home; time away from work, school, or home, and the amount of discomfort (eg, pain, itching, arthritis, interruption of sleep) while doing these activities. Impact on social activities; the role of psoriasis on effective interaction in the routine activities of work, school, and home. Included in this are attitudes of others at work, school, or home about psoriasis (eg, the idea that psoriasis is contagious; the appearance of skin, nails, and joints; the constant scaling) and the attitude of the patient toward these same aspects. Impact on psychologic aspects; the role of psoriasis on the patient s mental health. Included in this are the effects of a diminished body image caused by psoriasis, which results in withdrawal, depression, anxiety, feelings of inadequacy, and being sexually unappealing. BACKGROUND TO WHAT CONSTITUTES CLINICALLY SIGNIFICANT IMPROVEMENT The second purpose of this position paper is to bring attention to another important issue: What constitutes clinically significant improvement (CSI) in psoriasis? This is important both in clinical practice (medications that do not provide a particular patient a CSI are deemed not effective for that patient) and in regulatory decision-making (the FDA will not approve a treatment that does not provide a CSI). An attempt to define a CSI for clinical trials is a concept that is past due. The definition of CSI will have an impact on the availability of treatments to patients and their clinicians. The Medical Advisory Board applauds the FDA and others for directing attention to this issue. However, if too high a CSI criterion hurdle is required by the FDA, treatments with positive but limited effectiveness will not be approved. Moreover, a high CSI standard criterion would discourage industry from even attempting the development of new psoriasis treatments. A working definition of CSI A treatment that causes an improvement of 90% or more in a global assessment in clinical trials (trials designed to achieve statistical significance and that are properly blinded) clearly provides sufficient CSI to justify regulatory approval. Unfortunately, such a criterion would be met by few, if any, of the current
5 J AM ACAD DERMATOL VOLUME 43, NUMBER 2, PART 1 Krueger et al 285 psoriasis treatments. Some treatments may provide limited clearing of psoriasis in a broad range of patients or more extensive clearance in a few patients. Because of our desire to make effective psoriasis treatments accessible to patients, the Medical Advisory Board now concludes that an appropriate definition for CSI in clinical trials is any degree of improvement in a primary end point that achieves significance at a P value of.05 or less, compared with placebo, in clinical trials designed to achieve statistical significance and which are properly blinded. Psoriasis is a multigenic disease. 16 Thus it is likely that responses to agents will be selective, that is, some patients will have a constant response and others will not. Any treatment that consistently leads to clearing provides a CSI, even if it occurs in fewer than 5% of subjects, and would be a valuable clinical tool. The Medical Advisory Board feels strongly that such treatments should be available to the patients who would benefit from them. Consistent, predictable, and statistically significant responses, short of complete clearing with minimal or no side effects, are CSI. Approving treatments with limited but proven efficacy will permit clinicians the latitude to determine what is most effective for their patients. For example, drugs that cause modest improvement as a monotherapy may be much more effective when combined with another agent (eg, retinoids, UVL). 17,18 Moreover, any agent that predictably enhances QOL in a statistically significant fashion is providing a CSI. Examples would include agents that decrease itching or scaling. Finally, a drug that does not cause significant improvement may provide a CSI if it maintains patients in a disease-free state when used after psoriasis is brought to remission with another treatment approach. CONCLUSION Until we understand the molecular basis of psoriasis and have specific curative or consistently remittive therapies, the approving agencies should continue to assess new drug applications and approve those that are safe and demonstrate CSI in one or more end points. It is recognized that this invites approval of agents that will have limited beneficial effects. Perhaps the marketplace will effectively sort out those that are worthwhile from those that are not, but the current health care market may not be entirely effective in distinguishing cost from cost/ benefit. Because many treatments for psoriasis can be combined to work in an augmentative fashion in this life-altering disease, all therapeutic options need to be available. REFERENCES 1. Griffiths CEM, Voorhees JJ. Psoriasis, T cells and autoimmunity. J R Soc Med 1996;89: Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999;135: Kadunce DP, Krueger GG. Pathogenesis of psoriasis. Dermatol Clin 1995;13: Fleischer AB Jr, Feldman SR, Rapp SR, Reboussin DM, Clark AR, Rajashekhar V. Disease severity measures in a population of psoriasis patients: the symptoms of psoriasis correlate with self-administered psoriasis area severity index scores. J Invest Dermatol 1996;107: Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996;14: Ashcroft DM, Po ALW, Williams HC, Griffiths CEM. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999;141: Exum ML, Rapp SR, Feldman SR, Fleischer ABJ, Reboussin DM, Clark AR. Measuring severity of psoriasis: methodological issues. J Dermatol Treat 1998;7: Finlay AY. Quality of life assessments in dermatology. Semin Cutan Med Surg 1998;17: McKenna KE, Stern RS.The outcomes movement and new measures of the severity of psoriasis. J Am Acad Dermatol 1996; 34: Ashcroft DM, Li Wan PA, Williams HC, Griffiths CE. Quality of life measures in psoriasis: a critical appraisal of their quality. J Clin Pharm Ther 1998;23: Rapp SR, Exum ML, Reboussin DM, Feldman SR, Fleischer A, Clark A.The physical, psychological and social impact of psoriasis. J Health Psychol 1997;2: Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41: Feldman SR. Psoriasis treatment. Curr Probl Dermatol 1998;10: Rapp SR, Feldman SR, Fleischer ABJ, Reboussin DM, Exum ML. Health-related quality of life in psoriasis: a biopsychosocial model and measures. In: Rajagopalan R, Sherertz E, Anderson R, editors. Care management of skin diseases: life quality and economic impact. New York: Marcel Dekker; p Feldman SR, Fleischer AB Jr, Reboussin DM, Rapp SR, Bradham DD, Exum ML, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997;37: Jenisch S,Westphal E, Nair RP, Stuart P,Voorhees JJ, Christophers E, et al. Linkage disequilibrium analysis of familial psoriasis: identification of multiple disease-associated MHC haplotypes. Tissue Antigens 1999;53: Lowe NJ, Prystkowsky JH, Bourget T, Edelstein J, Nychay S, Armstrong R. Acitretin plus UVB therapy for psoriasis: comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 1991;24: Tanew A, Guggenbichler A, Honigsmann H, Geiger JM, Fritsch P. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol 1991;25:682-4.
CLINICAL BRIEFS. Unmet Needs in the Management of Plaque Psoriasis
CLINICAL BRIEFS Unmet Needs in the Management of Plaque Psoriasis A review of recently published data with an analysis for managed care decision makers Supplement to Volume 18, No. 1 Supplement 1 January
More informationPreetha selva et al. / International Journal of Phytopharmacology. 6(1), 2015, 42-46. International Journal of Phytopharmacology
International Journal of Phytopharmacology Journal homepage: www.onlineijp.com 42 e- ISSN 0975 9328 Print ISSN 2229 7472 IJP A CLINICAL STUDY TO EVALUATE THE EFFECT OF TOPICAL TAZAROTENE IN THE TREATMENT
More informationIs Monotherapy Treatment of Etanercept Effective Against Plaque Psoriasis?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Monotherapy Treatment of Etanercept
More informationCLINICAL BRIEFS. Considerations for the Clinical Assessment of the Patient With Plaque Psoriasis. By Amy Krajacic
CLINICAL BRIEFS Considerations for the Clinical Assessment of the Patient With Plaque Psoriasis By Amy Krajacic Senior Medical Editor, Custom Publications MediMedia USA, Yardley, Pa. A review of recently
More informationKey words: Psoriasis, Calcipotriol, Tazarotene. tazarotene. 16 ( 4 ) tazarotene calcipotriol ( 22 : 23-34, 2004)
In the treatment of plaque psoriasis, tazarotene was known to be effective, but its efficacy in a Taiwanese population has not been reported. Our purpose was to compare the efficacy, side effects and the
More informationNot All Clinical Trials Are Created Equal Understanding the Different Phases
Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact
More informationThe Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis
Clinical and Laboratory Investigations Dermatology 2005;210:194 199 DOI: 10.1159/000083509 Received: June 3, 2004 Accepted: October 4, 2004 The Psoriasis Area and Severity Index Is the Adequate Criterion
More informationX-Plain Psoriasis Reference Summary
X-Plain Psoriasis Reference Summary Introduction Psoriasis is a long-lasting skin disease that causes the skin to become inflamed. Patches of thick, red skin are covered with silvery scales. It affects
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists
MEDICAL ASSISTANCE HBOOK `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists A. Prescriptions That Require Prior Authorization All prescriptions for Cytokine and CAM Antagonists must
More informationYour psoriasis story. Print this out, answer the questions, then share it with your doctor
Your psoriasis story Print this out, answer the questions, then share it with your doctor 1 SYMPTOMS Surface Area Your doctor will use a variety of different factors to measure the severity of your disease,
More informationTreatment of Chronic Pain: Our Approach
Treatment of Chronic Pain: Our Approach Today s webinar was coordinated by the National Association of Community Health Centers, a partner with the SAMHSA-HRSA Center for Integrated Health Solutions SAMHSA
More informationPatient reported symptoms of psoriasis: results from the Psoriasis SELECT Patient Study
Patient reported symptoms of psoriasis: results from the Psoriasis SELECT Patient Study Zhang J 1, Swensen A 1, DiBonaventura M, Pierce A 3, Nyirady J 1 1 Novartis Pharmaceuticals Corporation, East Hanover,
More informationLaser Therapy for Plaque Psoriasis
Laser Therapy for Plaque Psoriasis Policy Number: Original Effective Date: MM.02.027 12/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/01/2015 Section: Medicine Place(s)
More informationCollaborative Association Study of Psoriasis. Gonçalo Abecasis, Anne Bowcock, James Elder, Jerry Krueger
Collaborative Association Study of Psoriasis Gonçalo Abecasis, Anne Bowcock, James Elder, Jerry Krueger Psoriasis Chronic, inflammatory skin condition Characteristic lesions, can affect substantial proportion
More informationEffectiveness of Inpatient Treatment on Quality of Life and Clinical Disease Severity in Atopic Dermatitis and Psoriasis Vulgaris A Prospective Study
Pharmacology and Treatment Dermatology 27;214:68 76 DOI: 1.1159/96916 Received: October 13, 25 Accepted: March 3, 26 Effectiveness of Inpatient Treatment on Quality of Life and Clinical Disease Severity
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationPsoriasis Treatment Transition Pathway
Psoriasis Treatment Transition Pathway A Treatment Support Tool Adapted from Circle Nottingham NHS Treatment Centre Psoriasis Pathway (under consultation) with support from Abbvie Ltd Treatment Pathways
More informationCAN-FITE BIOPHARMA LTD.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
More informationProduct: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac
PUBLIC SUMMARY DOCUMENT Product: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac Sponsor: Genepharm Australasia Ltd Date of PBAC Consideration: July 2007 1. Purpose
More information2-5 % Europeans A distressing, life-long, inflammatory disease Impairs patients Quality of Life
Psoriasis: 2-5 % Europeans A distressing, life-long, inflammatory disease Impairs patients Quality of Life 15-25%: moderate-to-severe disease - candidates for systemic therapies - often difficult to manage
More informationCutaneous Lymphoma FAST FACTS
Cutaneous Lymphoma FAST FACTS What is Cutaneous Lymphoma? Cutaneous lymphomas are types of non-hodgkin s lymphomas (NHL) that originate in the lymphocytes (white blood cells). Unlike most other types of
More informationHow Is OnabotulinumtoxinA Reimbursed For Chronic Migraine? Impact Of FDA Approval And The New CPT Code
How Is OnabotulinumtoxinA Reimbursed For Chronic Migraine? Impact Of FDA Approval And The New CPT Code Effective January 1, 2013, physicians will be able to report the new CPT code 64615 when performing
More informationMANAGEMENT OF CHRONIC NON MALIGNANT PAIN
MANAGEMENT OF CHRONIC NON MALIGNANT PAIN Introduction The Manitoba Prescribing Practices Program (MPPP) recognizes the important role served by physicians in relieving pain and suffering and acknowledges
More informationIF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN
+ IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start
More informationPsoriasis Can be Cured with Homoeopathy
Homoeopathy Clinic http://www.homoeopathyclinic.com Psoriasis Can be Cured with Homoeopathy Case Report / General Information What you should Know about Psoriasis? It is not a contagious disease. Psoriasis
More informationPSORIASIS AND ITS. Learn how vitamin D medications play an important role in managing plaque psoriasis
PLAQUE PSORIASIS AND ITS TREATMENTS Learn how vitamin D medications play an important role in managing plaque psoriasis 2 Understanding Plaque Psoriasis WHAT CAUSES PLAQUE PSORIASIS? No one knows exactly
More informationSCHEDULE. Medical College of Alabama, Birmingham. University of Arkansas School, Little Rock. Loma Linda University School, Loma Linda.
MEDICAL PRACTITIONERS ORDINANCE () Applied to Ascension by Chapter 5 of the 1950 Revised Edition of the Laws MEDICAL PRACTITIONERS (ASCENSION) REGULATIONS In exercise of the powers conferred upon the Governor
More informationCLINICAL MANIFESTATIONS OF PSORIATIC NAIL AT THE NATIONAL HOSPITAL OF DERMATOLOGY AND VENEREOLOGY (NHDV)
Southeast-Asian J. of Sciences: Vol. 2, No 1 (2013) pp. 101-107 CLINICAL MANIFESTATIONS OF PSORIATIC NAIL AT THE NATIONAL HOSPITAL OF DERMATOLOGY AND VENEREOLOGY (NHDV) Nguyen Huu Sau and Nguyen Minh Thu
More informationAn Assessment of the Cost-Utility of Therapy for Psoriasis
An Assessment of the Cost-Utility of Therapy for Psoriasis The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published
More informationThe Patient Journey in High Resolution
The Patient Journey in High Resolution Innovating for a richer understanding of the patient journey By Jackie Ilacqua Tel +1 201-574-8079 Email jackie.ilacqua@ipsos.com 1 xx-xx-xx Achieving a rich, yet
More informationPSORIASISforum. Initiating Narrow-band UVB for the Treatment of Psoriasis. Alice N. Do, D.O. a and John Y.M. Koo, M.D. b
PSORIASISforum Spring 2004 Vol. 10, No. 1 R E P R I N T E D F R O M A JOURNAL FOR N A T I O N A L P S O R I A S I S F O U N D A T I O N P R O F E S S I O N A L M E M B E R S Initiating Narrow-band UVB
More informationCONSENT FORM FOR PSYCHIATRIC DRUG TREATMENT
CONSENT FORM FOR PSYCHIATRIC DRUG TREATMENT This form has been adapted from: A Model Consent Form for Psychiatric Drug Treatment DOI: 10.1177/0022167800401006 Journal of Humanistic Psychology 2000; 40;
More informationParticipating in Alzheimer s Disease Clinical Trials and Studies
Participating in Alzheimer s Disease Clinical Trials and Studies FACT SHEET When Margaret was diagnosed with earlystage Alzheimer s disease at age 68, she wanted to do everything possible to combat the
More informationThe Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
More informationA Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa Purpose This study is currently patients. Verified by Neurotech Pharmaceuticals March 2007 Sponsored
More informationPATIENT RESOURCES: PSORIASIS
PATIENT RESOURCES: PSORIASIS Psoriasis is a persistent skin disorder in which there are red, thickened areas with silvery scales, most often on the scalp, elbows, knees, and lower back. Some cases, of
More informationEXHIBIT COORDINATING PROVISIONS-STATE/FEDERAL LAW, ACCREDITATION STANDARDS AND GEOGRAPHIC EXCEPTIONS MARYLAND
EXHIBIT COORDINATING PROVISIONS-STATE/FEDERAL LAW, ACCREDITATION STANDARDS AND GEOGRAPHIC EXCEPTIONS MARYLAND I. INTRODUCTION: Scope. To the extent of any conflict between the Agreement and this State
More informationThe efficacy of a far erythemogenic dose of narrow- band UVB phototherapy in chronic plaque type psoriasis
1 The efficacy of a far erythemogenic dose of narrow- band UVB phototherapy in chronic plaque type psoriasis ผ ว จ ย Rutsanee Akaraphanth MD, Yotsinee Kittipavara MD, Nataya Voravutinon MD, Usa Wachiratarapadorn
More informationWhat Cancer Patients Need To Know
Taking Part in Clinical Trials What Cancer Patients Need To Know NATIONAL INSTITUTES OF HEALTH National Cancer Institute Generous support for this publication was provided by Novartis Oncology. Taking
More informationPublic Forum on Psoriasis. 2011 National Series
Public Forum on Psoriasis 2011 National Series Jerry Tan MD FRCPC Schulich School of Medicine and Dentistry, University of Western Ontario Windsor, Ontario, Canada Presented at Caboto Club, Windsor, April
More informationPsoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis
Psoriasis Co-morbidities: Changing Clinical Practice Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology Psoriatic Arthritis Psoriatic Arthritis! 11-31% of patients with psoriasis have psoriatic
More informationAmerican Gastroenterological Association Institute Guideline on the Use of Pharmacological Therapies in the Treatment of Irritable Bowel Syndrome
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 American Gastroenterological Association Institute Guideline on the Use of Pharmacological Therapies in the Treatment of Irritable
More informationHEALTH SERVICES PROGRAM
HEALTH SERVICES PROGRAM The Board of Education will provide for the health and physical well being of students through the establishment of a district wide student Health Services Program in the school
More informationFor more information, please contact the National Psoriasis Foundation at 800-723-9166 or
For more information, please contact the National Psoriasis Foundation at 800-723-9166 or www.psoriasis.org. PSORIASIS 101: LEARNING TO LIVE IN THE SKIN YOU RE IN is part of an awareness program to educate
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationHow patients experience psoriasis: results from a European survey
ORIGINAL ARTICLE JEADV (2005) 19 (Suppl. 3), 2 6 DOI: 10.1111/j.1468-3083.2005.01329.x How patients experience psoriasis: results from a European survey Blackwell Publishing, Ltd. S Fouéré, L Adjadj,*
More informationTHE ROLE. Testimony United. of the. University. practicing. primary care. of care.
THE ROLE OF VALUE BASED INSURANCE DESIGN IN HEALTH CARE DELIVERY INNOVATION Testimony United States Senate Committee on Health, Education, Labor and Pensions A. Mark Fendrick, MD Professor of Internal
More informationGP Symposium Dermatology Dr Seow Hoong Foo Dr Shireen Velangi March 6th 2014
Psoriasis : It s not just skin de eep NICE Guidelines and Quality Standards: a collaboration to deliver quality care GP Symposium Dermatology y p gy Dr Seow Hoong Foo Dr Shireen Velangi March 6th 2014
More informationOsteoporosis Drug Development Moving Forward Public Workshop
Osteoporosis Drug Development Moving Forward Public Workshop November 4, 2015 Discussion Panel Members and Speakers Robert Adler, MD Chief, Endocrinology and Metabolism McGuire Veterans Affairs Medical
More informationGuidance for Industry
Guidance for Industry IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer U.S. Department of Health and Human Services Food and Drug Administration Center
More informationAmerican Academy of Pediatrics Bioethics Resident Curriculum: Case-Based Teaching Guides
American Academy of Pediatrics Bioethics Resident Curriculum: Case-Based Teaching Guides Session 1. Ethics Education and Available Resources Douglas J. Opel, MD, MPH, FAAP Overview Bioethics is relevant
More informationNaltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction. Frequently Asked Questions
Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction Frequently Asked Questions What is Naltrexone? Naltrexone is a prescription drug that effectively blocks the effects of heroin, alcohol,
More information02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION
Effective June 13, 2010 02-313, 02-373, 02-380, 02-383, 02-396 Chapter 21 page 1 02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION 313 BOARD OF DENTAL EXAMINERS 373 BOARD OF LICENSURE IN MEDICINE
More informationCOMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING FOR DERMATOLOGY
JUNE 2012 COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING WWW.CPSRXS. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Acne 2 Cutaneous Candidiasis
More informationResearch on Tablet Splitting
On behalf of the American Society of Consultant Pharmacists (ASCP) and its Ohio members, we are writing to express our concern over a recent proposal to implement a tablet splitting initiative under the
More informationScientific Thought. Opportunities in Biomedical Sciences. The Traditional Path. Stuart E. Ravnik, Ph.D. Observation
Opportunities in Biomedical Sciences Stuart E. Ravnik, Ph.D. Assistant Dean Graduate School of Biomedical Sciences Stuart E. Ravnik, Ph.D. July 24, 2003 Scientific Thought Observation Experimentation Hypothesis
More informationMultiple Sclerosis in Practice. An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report
Multiple Sclerosis in Practice An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report Clinical Context: Multiple Sclerosis in Practice Expert Commentary Jointly Sponsored by: and Clinical
More informationEMEA RM DRAFT GUIDANCE ISPE RESPONSE 1
EMEA RM DRAFT GUIDANCE ISPE RESPONSE 1 October 4, 2005 Guideline on Risk Management Systems for Medicinal Products for Human Use DRAFT London, 6 September 2005. This guideline will be included as chapter
More informationA Genetic Analysis of Rheumatoid Arthritis
A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.
More information2010 NRC R and S Rankings of UC Santa Cruz Research-Doctorate Programs
2010 NRC R and S Rankings of UC Santa Cruz Research-Doctorate Programs UCSC Program NRC Field Charts Anthropology Anthropology R Chart S Chart Astronomy & Astrophysics Astrophysics & Astronomy R Chart
More informationMEDICAL DEVICE & DIAGNOSTICS
to Guide Strategic Medical Device and Introduction Medical device and diagnostic makers face myriad challenges when developing a new product, including working within resource and financial constraints,
More informationEtanercept in childhood psoriasis: An experience from Kuwait
ORIGINAL ARTICLE Etanercept in childhood psoriasis: An experience from Kuwait Nawaf Al-Mutairi, MD, FRCP, Azari Al-Dhouki, MD, Mazen Al-Shiltawi, MD Department of Dermatology, Farwaniya Hospital, Kuwait
More informationTOPICAL TREATMENTS FOR PSORIASIS
TOPICAL TREATMENTS FOR PSORIASIS What are the aims of this leaflet? Patients with psoriasis are usually treated with preparations that are applied to the skin. This leaflet has been written to help you
More informationHow To Choose A Biologic Drug
North Carolina Rheumatology Association Position Statements I. Biologic Agents A. Appropriate delivery, handling, storage and administration of biologic agents B. Indications for biologic agents II. III.
More informationThe Role of the Patient/Consumer in Establishing a Dynamic Clinical Research Continuum:
The National Working Group on Evidence-Based Health Care The Role of the Patient/Consumer in Establishing a Dynamic Clinical Research Continuum: Models of Patient/Consumer Inclusion August 2008 The Working
More informationOnce the immune system is triggered, cells migrate from the blood into the joints and produce substances that cause inflammation.
HealthExchange Points For Your Joints An Arthritis Talk Howard Epstein, MD Orthopaedic & Rheumatologic Institute Rheumatic & Immunologic Disease Cleveland Clinic Beachwood Family Health & Surgery Center
More informationUnderstanding FTD Clinical Trials Continuing Education Training FTD Support Group Facilitators May 13, 2013
Understanding FTD Clinical Trials Continuing Education Training FTD Support Group Facilitators May 13, 2013 Our Shared Vision We envision a world where frontotemporal degeneration is understood, effectively
More informationList of Participating Schools
List of Participating Schools Alabama Calhoun Community College University of Alabama at Huntsville School of Nursing University of Alabama Birmingham Arizona University of Arizona School of Medicine California
More informationPHYSICIANS / SURGEONS
PHYSICIANS / SURGEONS American Academy of Audiology American Academy of Neurology American Academy of Physical Medicine & Rehabilitation American Academy of Ophthalmology Academy of Correctional Health
More informationClinical Trials: Questions and Answers
Clinical Trials: Questions and Answers Key Points Clinical trials are research studies that test how well new medical approaches work in people (see Question 1). Every clinical trial has a protocol, which
More information74 Full Text Available On www.ijupls.com. Medical Sciences. Original Article!!!
International Journal of Universal Pharmacy and Life Sciences 2(2): March-April 2012 INTERNATIONAL JOURNAL OF UNIVERSAL PHARMACY AND LIFE SCIENCES Medical Sciences Original Article!!! Received: 18-04-2012;
More informationPsoriasis. Student's Name. Institution. Date of Submission
Running head: PSORIASIS Psoriasis Student's Name Institution Date of Submission PSORIASIS 1 Abstract Psoriasis is a non-contagious chronic skin disease that is characterized by inflammatory and multiplying
More informationSummary 1. Comparative-effectiveness
Cost-effectiveness of Delta-9-tetrahydrocannabinol/cannabidiol (Sativex ) as add-on treatment, for symptom improvement in patients with moderate to severe spasticity due to MS who have not responded adequately
More informationGuidelines for Use of Controlled Substances for the Treatment of Pain
1.0 Purpose: Use of Controlled Substances for the Treatment of Pain The Physicians Advisory Committee for Controlled Substances of the Medical Society of Delaware supports the Federation of State Medical
More informationQuality of Life and Illness Perception in Adult EB Clinic Patients
Quality of Life and Illness Perception in Adult EB Clinic Patients Diane Beattie, Psychologist in Clinical Training Jacinta Kennedy, Principal Clinical Psychologist Katherine Sweeney, Clinical Nurse Specialist
More informationMedicines for Psoriatic Arthritis. A Review of the Research for Adults
Medicines for Psoriatic Arthritis A Review of the Research for Adults Is This Information Right for Me? Yes, this information is right for you if: Your doctor* has told you that you have psoriatic (pronounced
More informationFrequency and pattern of nail changes in patients with psoriasis vulgaris
Original Article Frequency and pattern of nail changes in patients with psoriasis vulgaris Ijaz Ahmed, Sarwat Nasreen Department of Dermatology, Ziauddin University Hospital, KDLB Campus, Karachi Abstract
More informationEastern Washington Medical-Dental Health Summit III
Eastern Washington Medical-Dental Health Summit III THURSDAY MARCH 3, 2016 Community Health VIP Reception Three Rivers Convention Center: 5:30-7:30 pm FRIDAY MARCH 4, 2016 Medical Dental Summit Integrating
More informationFocus on Assessment. Teaching Pain Assessment and Management: Pearls for Caring for Patients with Pain. #1. Pain is a Universal Experience.
Teaching Pain Assessment and Management: Pearls for Caring for Patients with Pain Jennifer Parsons, FNP Duke Pain Medicine Adaptive Teaches us about our environment Demands attention Can be all consuming
More informationCommissioning Policy: Defining the boundaries between NHS and Private Healthcare April 2013 Reference : NHSCB/CP/12
Commissioning Policy: Defining the boundaries between NHS and Private Healthcare April 2013 Reference : NHSCB/CP/12 NHS Commissioning Board Commissioning Policy: Defining the Boundaries between NHS and
More informationExpanded Access Programs. Richard Klein Office of Special Health issues Food and Drug Administration
Expanded Access Programs Richard Klein Office of Special Health issues Food and Drug Administration Expanded Access Programs (EAPs) What is expanded access? History Legislative background General principles
More informationTechnological platforms
Advitech Advitech is a life sciences & technology company Its mission is to discover and commercialize proprietary and evidence-based natural health products Focus on milk, whey and bovine colostrum R&D,
More informationWaiver to Allow Participation in a Food and Drug Administration Advisory Committee
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring MD 20993 Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DATE:
More informationComparison of the Effect of Azelaic Acid 20% And Clindamycin 1% In the Treatment of Mild And Moderate Acne. Abstract
Original Article Comparison of the Effect of Azelaic Acid 20% And Clindamycin 1% In the Treatment of Mild And Moderate Acne Soudabeh Tirgar Tabari, MD Ali Akbar Moghadam Nia, PharmD Karimollah Hajian Amirmajid
More informationUNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR 2015
UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR 2015 ANESTHESIOLOGY- 4 Beth Israel Deaconess Medical Center, Boston MA Oregon Health & Science University, Portland OR St. Louis Children s
More informationCHAPTER FIVE ETHICS AND MEDICAL RESEARCH
94 CHAPTER FIVE ETHICS AND MEDICAL RESEARCH Sleeping sickness is back Robert Patric/CORBIS SYGMA 95 Medical Medical Ethics Ethics Manual Manual Principal Ethics Features and Medical of Medical Research
More informationHow To Weigh Data From A Study
PRINCIPLES ON RESPONSIBLE SHARING OF TRUTHFUL AND NON-MISLEADING INFORMATION ABOUT MEDICINES WITH HEALTH CARE PROFESSIONALS AND PAYERS INTRODUCTION In the era of data-driven medicine, where all parties
More informationSeptember 5, 2014. Linda Stewart Vice President, National Lab Program UnitedHealthcare Group P.O. Box 1459 Minneapolis, MN 55440 1459
September 5, 2014 Linda Stewart Vice President, National Lab Program UnitedHealthcare Group P.O. Box 1459 Minneapolis, MN 55440 1459 Re: UnitedHealthcare Laboratory Benefit Management Program Dear Ms.
More informationHomeopathy. Homeopathy is one of the more controversial forms of CAM. Much of. Treatment Method
Homeopathy Homeopathy is one of the more controversial forms of CAM. Much of the controversy is due to the fact that the basic principles of homeopathy are in conflict with many of the fundamental concepts
More informationWhat is Multiple Sclerosis? Gener al information
What is Multiple Sclerosis? Gener al information Kim, diagnosed in 1986 What is MS? Multiple sclerosis (or MS) is a chronic, often disabling disease that attacks the central nervous system (brain and spinal
More informationAging Well - Part V. Hormone Modulation -- Growth Hormone and Testosterone
Aging Well - Part V Hormone Modulation -- Growth Hormone and Testosterone By: James L. Holly, MD (The Your Life Your Health article published in the December 4th Examiner was a first draft. It was sent
More informationUser Centric Product Design for Greater End-User Adherence. Primary Data on a 360 o Analysis
User Centric Product Design for Greater End-User Adherence Primary Data on a 360 o Analysis Panel Discussion Gary Hall, Jr. 10 time Olympic Medalist & Diabetes Patient Russell Rothman, MD, MPP Assistant
More informationThe NIH Roadmap: Re-Engineering the Clinical Research Enterprise
NIH BACKGROUNDER National Institutes of Health The NIH Roadmap: Re-Engineering the Clinical Research Enterprise Clinical research is the linchpin of the nation s biomedical research enterprise. Before
More informationGoal 2. To produce humanitarian physicians with high moral and ethical standards.
THE ASK CURRICULUM The central challenge of the modern medical curriculum is to educate future physicians who will continue to learn throughout their careers. The curriculum of the Robert Wood Johnson
More informationc. determine the factors that will facilitate/limit physician utilization of pharmacists for medication management services.
Consumer, Physician, and Payer Perspectives on Primary Care Medication Management Services with a Shared Resource Pharmacists Network Marie Smith, PharmD and Michlle Breland, PhD University of Connecticut,
More informationPatient Information Leaflet: Part 1 select-d
Patient Information Leaflet: Part 1 select-d Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism Introduction This
More informationTargeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia EXECUTIVE SUMMARY. New England Healthcare Institute
Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia New England Healthcare Institute NEHI Innovation Series March 2004 Executive Summary From drugs and medical devices, to information
More informationNeutral Superoxidized solution vs. benzoyl peroxide gel 5% in the treatment of. Superoxidized solution (SOS) is an electrochemically processed aqueous
Neutral Superoxidized solution vs. benzoyl peroxide gel 5% in the treatment of acne vulgaris: a randomized open-label clinical trial. Summary. Superoxidized solution (SOS) is an electrochemically processed
More informationNational MS Society Information Sourcebook www.nationalmssociety.org/sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers
More informationJerry Bagel, MD of Windsor Dermatology Home of the Psoriasis Treatment Center of Central New Jersey
JULY 2012 Jerry Bagel, MD of Windsor Dermatology Home of the Psoriasis Treatment Center of Central New Jersey Restoring Quality of Life for Psoriatic Patients Throughout NJ and Beyond Jerry Bagel, MD of
More information